Prophase Labs (PRPH) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual Meeting scheduled for July 18, 2025, to elect four directors, ratify the auditor, and hold advisory votes on executive compensation and its frequency.
Board recommends voting for all director nominees, auditor ratification, executive compensation approval, and a triennial say-on-pay vote.
Proxy materials and annual report are available online; shareholders can vote by mail, phone, or internet.
Voting matters and shareholder proposals
Four proposals: election of directors, auditor ratification, advisory say-on-pay, and advisory vote on say-on-pay frequency.
Board recommends voting for all proposals and for a three-year frequency on say-on-pay.
No other shareholder proposals or nominations were received for this meeting.
Shareholders may submit proposals for the 2026 meeting by specified deadlines.
Board of directors and corporate governance
Board consists of four members, three of whom are independent under Nasdaq rules.
Carolina Abenante appointed as independent director, to join Audit Committee after the meeting to restore Nasdaq compliance.
Board committees: Audit, Compensation, and Nominating, all with independent members.
Board leadership combines CEO and Chairman roles; no lead independent director.
Board and committees met regularly in 2024, with high attendance.
Latest events from Prophase Labs
- Major cash recovery and cancer test commercialization set to transform financial outlook.PRPH
2025 ThinkEquity Conference3 Feb 2026 - Q2 losses deepen, but new launches and strategic moves set stage for strong H2 growth.PRPH
Q2 20241 Feb 2026 - Q3 losses and revenue drop offset by new launches and cost cuts, setting up strong future growth.PRPH
Q3 202414 Jan 2026 - Reverse merger LOI with ABL offers $10M dividend, $50M receivables, and majority control.PRPH
Status Update19 Dec 2025 - Patent approval, product expansion, and $50M receivables recovery drive growth outlook.PRPH
Status Update19 Dec 2025 - Registering $291.6M in securities to fund biotech, genomics, and diagnostics growth.PRPH
Registration Filing16 Dec 2025 - BE-Smart test validated and patented, $50M receivables targeted, genomics platform expanding.PRPH
Investor Presentation8 Dec 2025 - Major equity, capital, and governance changes proposed to enable a crypto treasury strategy.PRPH
Proxy Filing2 Dec 2025 - Shareholders will vote on equity plans, a 1B share authorization, and a $15M buyback program.PRPH
Proxy Filing2 Dec 2025